Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo
Biological PsychiatryPublished 1 November 1995
Louis F. Fabre, F.S. Abuzzahab, Mohamed Amin, James L. Claghorn, J. Mendels, William M. Petrie
Citations184
SJR quartileQ1
SJR score4.68
SNIP2.24
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The results of this study show that sertraline 50 mg once daily is as effective as higher dosages for the treatment of major depression with fewer side effects and therapy discontinuations.
Abstract
In a 6-week, randomized, double-blind, multicenter trial, sertraline 50 mg, 100 mg, or 200 mg, or placebo, was administered once daily to 369 patients with DSM-III-defined major depression. Efficacy variables included changes from baseline scores for total Hamilton Rating Scale for Depression (HAMD), HAMD Bech Depression Cluster, Clinical Global Impressions (CGI) Severity, CGI Improvement, and Profile of Mood States Depression/Dejection Factor. For the evaluable-patients analysis, all sertraline groups showed significantly (p < 0.05 or better) greater improvements in all efficacy variables except one when compared with the placebo group. For the all-patients analysis, all efficacy variables in the 50 mg group were statistically significantly (p < 0.05) better than placebo. Side effects increased with increasing dosage but were usually mild and well tolerated. The results of this study show that sertraline 50 mg once daily is as effective as higher dosages for the treatment of major depression with fewer side effects and therapy discontinuations.
Keywords
Medicine
Encyclopedia of Social WorkDiagnostic and Statistical Manual of Mental Disorders
109,983 Citations2013Janet B. W. Williams, Michael B. First
Journal of Neurology Neurosurgery & PsychiatryA RATING SCALE FOR DEPRESSION
32,633 Citations1960M. Hamilton
The present scale has been devised for use only on patients already diagnosed as suffering from affective disorder of depressive type, used for quantifying the results of an interview, and its value depends entirely on the skill of the interviewer in eliciting the necessary information.
Acta Psychiatrica ScandinavicaQUANTITATIVE RATING OF DEPRESSIVE STATES
490 Citations1975Per Bech, L. F. Gram +4 more
A step‐by‐step analysis of Beck's and Hamilton's rating scales showed that both, scales failed to differentiate adequately between moderate and severe depression measured by a global clinical assessment.
Life SciencesBlockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
391 Citations1993Carolyn Watson, Elliott Richelson
Although none of the drugs was potent for [3H]dopamine uptake blockade, sertraline was the most potent (Ki = 260 nM).
PubMedAntidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression.
262 Citations1990Fred Reimherr, G Chouinard +6 more
The amitriptyline group showed a higher proportion of anticholinergic and sedative side effects and dizziness compared with patients who received either sertraline or placebo, and showed a significantly greater improvement from baseline than the placebo group.
Journal of Pharmacology and Experimental TherapeuticsSertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin.
258 Citations1983B. Kenneth Koe, Arthur D. Weissman +2 more
It is proposed that selective blockade of serotonin reuptake can induce activation of norepinephrine neurons and subsequent down-regulation of norpinephrine receptors and that sertraline, a highly selective inhibitor of serotonin uptake, may be an efficacious antidepressant without anticholinergic or cardiovascular side-effects.
European Journal of PharmacologyAntidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression
230 Citations1987G.A. Kennett, Colin T. Dourish +1 more
The results suggest that 5-HT1A agonists may have rapid antidepressant properties and that vehicle-treated restrained rats showed reduced locomotor activity and increased defaecation in an open field test the day after the end of restraint.
Journal of Clinical PsychopharmacologyEffects of Antidepressant Medication on Sexual
189 Citations1986Wilma Harrison, Judith G. Rabkin +5 more
Antidepressant-related sexual dysfunction may be of clinical importance for medication compliance in view of current recommendations that antidepressants be administered for longer periods as maintenance therapy or for prophylaxis.
PubMedFluoxetine-induced sexual dysfunction.
178 Citations1990John B. Herman
Findings shed light on the epidemiology of OCD and its association with other disorders, and point to a neurophysiologic model involving serotonin.
PubMedClinical overview of serotonin reuptake inhibitors.
167 Citations1990Karl Rickels, Edward E. Schweizer
Serotonin reuptake inhibitors have not replaced the tricyclics, but are a useful addition to the variety of drugs currently used for the treatment of depression.
Life SciencesBiogenic amine hypothesis of affective disorders
149 Citations1979David L. Garver, John M. Davis
PubMedThe role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction.
124 Citations1991John Zajecka, J. Paul Fawcett +3 more
The authors report 6 cases of orgasm dysfunction associated with the use of fluorxetine in 77 depressed outpatients and discusses the possible effects of serotonin on central, spinal, and peripheral anatomical areas in relation to drug-induced sexual dysfunction.
Raven Press eBooksAntidepressants : neurochemical, behavioral, and clinical perspectives
115 Citations1981S.J. Enna, Jeffrey B. Malick +1 more
This volume is noteworthy in that it does provide the salient biological and psychological knowledge currently available to advance hypotheses for further study, and provides important data for the clinical application of ECT.
PubMedOptimal dose regimen for paroxetine.
108 Citations1992David L. Dünner, G. C. Dunbar
The dose regimen for paroxetine in the treatment of depression has been well established through a number of individual dosing studies and analyses from the worldwide clinical data base and the starting dose is 20 mg/day.
PubMedThe pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
82 Citations1992I.F. Tulloch, A M Johnson
This pharmacologic and pharmacokinetic profile, taken together with extensive clinical data, indicates that paroxetine is a valuable addition to the physician's armamentarium for the treatment of depression.
Clinical NeuropharmacologyUse of Specific Serotonin Uptake Inhibitors as Antidepressants
52 Citations1985Louis Lemberger, Ray W. Fuller +1 more
PubMedNeuroleptic treatment in the borderline patient: advantages and techniques.
49 Citations1987J. Mendels
A low-dose neuroleptic strategy is indicated in borderline personality disorder as an acute treatment for symptoms of anger, hostility and suspiciousness, referential thinking and paranoid ideation, anxiety and dissociation, depressed mood, and related behavioral dyscontrol.
PubMedA fixed-dose clinical trial of fluoxetine in outpatients with major depression.
48 Citations1987Louis F. Fabre, H. Paul Putman
The 20-mg dose produced improvement of depression in the moderate-severe depression group as expressed in significant reductions of scores on the Hamilton Rating Scale for Depression and the Patient Global Impressions scale.
PubMedPsychotropic drug induced weight gain: mechanisms and management.
42 Citations1988Jerrold G. Bernstein
Evidence suggests that compounds, which either antagonize or downregulate serotonin receptors, are more likely to stimulate carbohydrate hunger and weight gain, and Amitriptyline, chlorpromazine, mesoridazines, thioridazine, and lithium are most likely to produce weight gain.
European Journal of PharmacologySertraline, a selective inhibitor of serotonin uptake, induces subsensitivity of β-adrenoceptor system of rat brain
39 Citations1987B. Kenneth Koe, Susan W. Koch +3 more
Findings suggest that increased serotonergic activity may be involved in the induction of subsensitivity of the beta-adrenoceptor system of rat brain by sertraline.
Drug Development ResearchDouble‐blind dose determination study of a new antidepressant—sertraline
13 Citations1986William Guy, Gregory Manov +1 more
The efficacy of sertraline could not be demonstrated under these design constraints, although differential dose level effects were indicated and doses up to 100 mg/day would appear to be more clinically appropriate than higher dosage levels.
Clinical NeuropharmacologySERTRALINE IN THE TREATMENT OF DEPRESSION IN PRIMARY CARE
2 Citations1992Paul M. Thompson, J J Martindale +1 more